Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Releasing Hormone (GHRH) Analog |
| Risk Level | Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Nightly |
| Estimated Half-Life | Approximately 10–20 Minutes |
| Primary Research Interest | Growth Hormone Support / Recovery / Sleep Optimization |
This material is provided strictly for educational and informational purposes related to peptide research and endocrine compounds. Sermorelin is a biologically active compound that may significantly influence hormonal pathways and endocrine function. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 200 mcg = 0.060 mL (6.0 units)
• 300 mcg = 0.090 mL (9.0 units)
2. Route of Administration
Sermorelin is most commonly administered as a subcutaneous injectable compound.
- Primary Route: SubQ Injection
- Preferred Timing: Evening / Bedtime administration
- Administration Notes: Commonly discussed approximately 1 hour after the final meal of the day
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 200–300 mcg nightly
- Frequency: Every PM, approximately 1 hour after the final meal
- Cycle Length: 6 months on / 3 months off
- Special Notes: Long term use or using during the day versus at bedtime can lead to long term pituitary dysfunction and an abnormal decline in naturally occurring HGH levels.
4. Summary
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone production through pituitary signaling pathways.
Unlike direct growth hormone administration, Sermorelin attempts to enhance the body’s own pulsatile HGH secretion patterns.
5. Mechanism of Action
Sermorelin functions by binding GHRH receptors within the anterior pituitary gland, stimulating release of endogenous human growth hormone (HGH).
This signaling cascade may influence:
- IGF-1 production
- Recovery processes
- Sleep quality
- Protein synthesis
- Body composition
- Tissue repair mechanisms
Because Sermorelin relies on endogenous hormone production, its effects are generally considered more physiologically regulated than exogenous HGH administration.
6. Potential Benefits
- Increased endogenous HGH production
- Potential improvements in sleep quality
- Improved recovery capacity
- Possible body composition improvements
- Enhanced recovery from training stress
- Potential improvements in tissue repair processes
7. Potential Risks / Side Effects
Moderate
- Water retention
- Numbness or tingling sensations
- Headaches
- Flushing
- Injection site irritation
- Potential endocrine dysregulation
- Possible pituitary signaling disruption with inappropriate long-term use
8. Half-Life
Sermorelin has a relatively short estimated half-life of approximately 10–20 minutes.
Despite its short circulation time, downstream growth hormone signaling effects may persist longer due to stimulated endogenous HGH release.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Uncontrolled endocrine disorders
- Pregnancy or breastfeeding
- Severe pituitary dysfunction
- Untreated sleep apnea
11. Research References
- PubMed
- NIH Publications
- Growth hormone physiology literature
- Peer-reviewed endocrinology journals
CKF Tide Tables 